Euretina Congress
Euretina Congress
Source/Disclosures
Source:

Tadayoni R. Oculis OCS-01 phase 2 study results: A topical therapeutic for DME. Presented at: Euretina; Oct. 2-4, 2020 (virtual meeting).

October 15, 2020
1 min watch
Save

VIDEO: First topical treatment for DME may lead to paradigm shift

Source/Disclosures
Source:

Tadayoni R. Oculis OCS-01 phase 2 study results: A topical therapeutic for DME. Presented at: Euretina; Oct. 2-4, 2020 (virtual meeting).

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

At the virtual Euretina meeting, Ramin Tadayoni, MD, PhD, presents the results of the phase 2 study of OCS-01, the first topical treatment for diabetic macular edema.

Eye drops for DME are a long-awaited option and will be an interesting alternative treatment for patients in whom intravitreal injections are not suitable.